Current and future clinical applications of cardiac positron emission tomography

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 836-848

  Ohira, Hiroshi ^a   Ardle, Brian Mc ^a   Cocker, Myra S ^a   deKemp, Robert A ^a   DaSilva, Jean N ^a   Beanlands, Rob S ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Inflammation imaging; Myocardial perfusion imaging; Myocardial viability imaging; Noninvasive imaging; Positron emission tomography

Indexed keywords

AMMONIA N 13; FLUORODEOXYGLUCOSE F 18; FLURPIRIDAZ F 18; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RUBIDIUM 82; SODIUM FLUORIDE F 18; TECHNETIUM 99M; TETROFOSMIN TC 99M; THALLIUM 201; TRACER; WATER O 15;

ALGORITHM; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CYCLOTRON; DIAGNOSTIC ACCURACY; EXERCISE; FRACTIONAL FLOW RESERVE; HALF LIFE TIME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); MYOCARDIAL PERFUSION IMAGING; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOVASCULAR DISEASES; HEART; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84875515247     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0213     Document Type: Review

References (100)

1. Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V: Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. Am J Cardiol 1979; 43: 200-208.
2. Schelbert HR, Wisenberg G, Phelps ME, Gould KL, Henze E, Hoffman EJ, et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI: Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol 1982; 49: 1197-1207.
3. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
4. Sampson UK, Dorbala S, Limaye A, Kwong R, Di Carli MF. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol 2007; 49: 1052-1058.
5. Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, et al. CCS/CAR/CANM/CNCS/CANSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease: executive summary. Can J Cardiol 2007; 23: 107-119.
6. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99 m sestamibi SPECT. J Nucl Cardiol 2006; 13: 24-33.
7. Yoshinaga K, Chow BJ, Williams K, Chen L, deKemp RA, Garrard L, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006; 48: 1029-1039.
8. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 2011; 58: 740-748.
9. Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of stress myocardial perfusion positron emission tomography: Results from a multicenter observational registry. J Am Coll Cardiol 2013; 61: 176-184.
10. Bengel FM. Leaving relativity behind: Quantitative clinical perfusion imaging. J Am Coll Cardiol 2011; 58: 749-751.
11. Marwick TH, MacIntyre WJ, Lafont A, Nemec JJ, Salcedo EE. Metabolic responses of hibernating and infarcted myocardium to revascularization: A follow-up study of regional perfusion, function, and metabolism. Circulation 1992; 85: 1347-1353.
12. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: Diagnosis and patient outcomes. Curr Probl Cardiol 2007; 32: 375-410.
13. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: Role of positron emission tomography. Eur Heart J 2010; 31: 2984-2995.
14. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50: 2002-2012.
15. Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER Jr, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 1993; 22: 368-375.
16. Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: An analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart 1999; 81: 262-270.
17. Vesalainen RK, Pietila M, Tahvanainen KU, Jartti T, Teras M, Nagren K, et al. Cardiac positron emission tomography imaging with [11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Am J Cardiol 1999; 84: 568-574.
18. Fallavollita JA, Banas MD, Suzuki G, deKemp RA, Sajjad M, Canty JM Jr. 11C-meta-hydroxyephedrine defects persist despite functional improvement in hibernating myocardium. J Nucl Cardiol 2010; 17: 85-96.
19. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with 13NNH3/ 18F-FDG PET. J Nucl Med 2003; 44: 1030-1036.
20. Theron J, Tyler JL. Takayasu's arteritis of the aortic arch: Endovascular treatment and correlation with positron emission tomography. Am J Neuroradiol 1987; 8: 621-626.
21. Tahara N, Imaizumi T, Virmani R, Narula J. Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis. J Nucl Med 2009; 50: 331-334.
22. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emis sion tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26: 1538-1543.
23. Mc Ardle BA, Leung E, Ohira H, Cocker MS, Dekemp RA, Dasilva J, et al. The role of F18-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013 January 4, doi:10.1007/s12350-012-9668-9 [Epub ahead of print].
24. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
25. Conti M. State of the art and challenges of time-of-flight PET. Phys Med 2009; 25: 1-11.
26. deKemp RA, Yoshinaga K, Beanlands RS. Will 3-dimensional PETCT enable the routine quantification of myocardial blood flow? J Nucl Cardiol 2007; 14: 380-397.
27. Klein R, Beanlands RS, deKemp RA. Quantification of myocardial blood flow and flow reserve: Technical aspects. J Nucl Cardiol 2010; 17: 555-570.
28. Mc Ardle B, Ziadi MC, Ruddy TD, Beanlands RS. Nuclear perfusion imaging for functional evaluation of patients with known or suspected coronary artery disease: The future is now. Future Cardiol 2012; 8: 603-622.
29. Hunter C, Ziadi MC, Etele J, Hill J, Beanlands RS, deKemp RA. New effective dose estimates for rubidium-82 based on dynamic PET/CT imaging in humans. Canadian Cardiovascular Society (CCS) CCS185 poster: Imaging: Atherosclerosis and coronary artery disease Sunday, October 24, 2010. Can J Cardiol 2010; 26(Suppl D): 40D-42D.
30. Senthamizhchelvan S, Bravo PE, Lodge MA, Merrill J, Bengel FM, Sgouros G. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med 2011; 52: 485-491.
31. Chow BJ, Beanlands RS, Lee A, DaSilva JN, deKemp RA, Alkahtani A, et al. Treadmill exercise produces larger perfusion defects than dipyridamole stress N-13 ammonia positron emission tomography. J Am Coll Cardiol 2006; 47: 411-416.
32. Maddahi J. Properties of an ideal PET perfusion tracer: New PET tracer cases and data. J Nucl Cardiol 2012; 19(Suppl 1): S30-S37.
33. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010; 3: 623-640.
34. Mc Ardle BA, Dowsley TF, Dekemp RA, Wells GA, Beanlands RS. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease? A systematic review and meta-analysis. J Am Coll Cardiol 2012; 60: 1828-1837.
35. Ziadi MC, Beanlands RS. The clinical utility of assessing myocardial blood flow using positron emission tomography. J Nucl Cardiol 2010; 17: 571-581.
36. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, et al. BMS-747158-02: A novel PET myocardial perfusion imaging agent. J Nucl Cardiol 2007; 14: 789-798.
37. Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med 2008; 49: 630-636.
38. Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: Comparison to 13Nammonia and validation with microspheres in a pig model. Circulation 2009; 119: 2333-2342.
39. Yoshinaga K. Updated Health, Labor and Welfare Ministry's approval of cardiac positron emission tomography. Nucl Cardiol 2013; 15: 31.
40. Heo J, Powers J, Iskandrian AE. Exercise-rest same-day SPECT sestamibi imaging to detect coronary artery disease. J Nucl Med 1997; 38: 200-203.
41. Bateman TM, Heller GV, McGhie AI, Courter SA, Golub RA, Case JA, et al. Multicenter investigation comparing a highly efficient half-time stress-only attenuation correction approach against standard rest-stress Tc-99 m SPECT imaging. J Nucl Cardiol 2009; 16: 726-735.
42. Go RT, Marwick TH, MacIntyre WJ, Saha GB, Neumann DR, Underwood DA, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 1990; 31: 1899-1905.
43. Stewart RE, Schwaiger M, Molina E, Popma J, Gacioch GM, Kalus M, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol 1991; 67: 1303-1310.
44. Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: A bivariate meta-analysis. Circ Cardiovasc Imaging 2012; 5: 700-707.
45. Beanlands RS, Youssef G. Diagnosis and prognosis of coronary artery disease: PET is superior to SPECT: Pro. J Nucl Cardiol 2010; 17: 683-695.
46. Parkash R, deKemp RA, Ruddy TD, Kitsikis A, Hart R, Beauchesne L, et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 2004; 11: 440-449.
47. Lima RS, Watson DD, Goode AR, Siadaty MS, Ragosta M, Beller GA, et al. Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. J Am Coll Cardiol 2003; 42: 64-70.
48. Ziadi MC, Dekemp RA, Williams K, Guo A, Renaud JM, Chow BJ, et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease? J Nucl Cardiol 2012; 19: 670-680.
49. Rischpler C, Higuchi T, Fukushima K, Javadi MS, Merrill J, Nekolla SG, et al. Transient ischemic dilation ratio in 82Rb PET myocardial perfusion imaging: Normal values and significance as a diagnostic and prognostic marker. J Nucl Med 2012; 53: 723-730.
50. Dorbala S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging 2009; 2: 846-854.
51. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van't Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213-224.
52. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367: 991-1001.
53. Johnson NP, Kirkeeide RL, Gould KL. Is discordance of coronary flow reserve and fractional flow reserve due to methodology or clinically relevant coronary pathophysiology? JACC Cardiovasc Imaging 2012; 5: 193-202.
54. Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006; 47: 1188-1195.
55. Schindler TH, Facta AD, Prior JO, Cadenas J, Zhang XL, Li Y, et al. Structural alterations of the coronary arterial wall are associated with myocardial flow heterogeneity in type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging 2009; 36: 219-229.
56. Kaufmann PA, Gnecchi-Ruscone T, hM, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: Vitamin C restores coronary microcirculatory function. Circulation 2000; 102: 1233-1238.
57. Alexanderson E, Jacome R, Jimenez-Santos M, Ochoa JM, Romero E, Cabral MA, et al. Evaluation of the endothelial function in hypertensive patients with 13N-ammonia PET. J Nucl Cardiol 2012; 19: 979-986.
58. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol 1997; 80: 865-870.
59. Tio RA, Dabeshlim A, Siebelink HM, de Sutter J, Hillege HL, Zeebregts CJ, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med 2009; 50: 214-219.
60. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009; 54: 150-156.
61. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011; 124: 2215-2224.
62. Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 1998; 273: 29530-29539.
63. Heyndrickx GR, Wijns W, Vogelaers D, Degrieck Y, Bol A, Vandeplassche G, et al. Recovery of regional contractile function and oxidative metabolism in stunned myocardium induced by 1-hour circumflex coronary artery stenosis in chronically instrumented dogs. Circ Res 1993; 72: 901-913.
64. Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, et al. Program of cell survival underlying human and experimental hibernating myocardium. Circ Res 2004; 95: 433-440.
65. Canty JM Jr, Fallavollita JA. Chronic hibernation and chronic stunning: A continuum. J Nucl Cardiol 2000; 7: 509-527.
66. Mielniczuk LM, Beanlands RS. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit? Imaging-guided selection of patients with ischemic heart failure for high-risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging 2012; 5: 262-270.
67. Underwood SR, Bax JJ, vom Dahl J, Henein MY, Knuuti J, van Rossum AC, et al. Imaging techniques for the assessment of myocardial hibernation: Report of a study group of the European Society of Cardiology. Eur Heart J 2004; 25: 815-836.
68. Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R, et al. Prediction of reversible ischemia after revascularization: Perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91: 1697-1705.
69. Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Moerlein SM, Sobel BE, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992; 20: 569-577.
70. D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: A substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009; 2: 1060-1068.
71. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73: 527-533.
72. Beanlands RS, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M, et al. Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40: 1735-1743.
73. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002; 39: 1151-1158.
74. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364: 1617-1625.
75. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability Circulation 2008; 117: 103-114.
76. Pagano D, Bonser RS, Camici PG. Myocardial revascularization for the treatment of post-ischemic heart failure. Curr Opin Cardiol 1999; 14: 506-509.
77. Dwivedi G, Chan KL, Friedrich MG, Beanlands RS. Cardiovascular imaging: New directions in an evolving landscape. Can J Cardiol 2013; 29: 257-259.
78. Cocker MS, Mc Ardle B, Spence JD, Lum C, Hammond RR, Ongaro DC, et al. Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: What Leonardo da Vinci could not see. J Nucl Cardiol 2012; 19: 1211-1225.
79. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography Circulation 2002; 105: 2708-2711.
80. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831.
81. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009; 50: 563-568.
82. Perry A, Vuitch F. Causes of death in patients with sarcoidosis: A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995; 119: 167-172.
83. Ohira H, Tsujino I, Yoshinaga K. 18F-fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011; 38: 1773-1783.
84. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A doseresponse study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979; 7: 531-533.
85. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16: 801-810.
86. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45: 1989-1998.
87. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45: 1683-1690.
88. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933-941.
89. Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: Establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 2012 December 13, doi:10.1016/j.cjca.2012.09.009 [Epub ahead of print].
90. Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: A call for prospective studies of newer imaging techniques. Eur Respir J 2007; 29: 418-422.
91. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010; 3: 1219-1228.
92. Fallavollita JA, Luisi AJ Jr, Michalek SM, Valverde AM, deKemp RA, Haka MS, et al. Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. Contemp Clin Trials 2006; 27: 374-388.
93. Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP. Evidence for the efficacy of ARBs across the cardiovascular continuum. Curr Med Res Opin 2010; 26: 1203-1218.
94. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
95. Sun Y. Intracardiac renin-angiotensin system and myocardial repair/ remodeling following infarction. J Mol Cell Cardiol 2010; 48: 483-489.
96. Fukushima K, Bravo PE, Higuchi T, Schuleri KH, Lin X, Abraham MR, et al. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors. J Am Coll Cardiol 2012; 60: 2527-2534.
97. Gaemperli O, Shalhoub J, Owen DR, Lamare F, Johansson S, Fouladi N, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-pk11195 positron emission tomography/computed tomography. Eur heart J 2012; 33: 1902-1910.
98. Lamare F, Hinz R, Gaemperli O, Pugliese F, Mason JC, Spinks T, et al. Detection and quantification of large-vessel inflammation with 11C-(r)-pk11195 PET/CT. J Nucl Med 2011; 52: 33-39.
99. Laufer EM, Winkens HM, Corsten MF, Reutelingsperger CP, Narula J, Hofstra L. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled annexin A5. Q J Nucl Med Mol Imaging 2009; 53: 26-34.
100. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: A novel marker of plaque biology. J Am Coll Cardiol 2012; 59: 1539-1548.